Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-two research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $630.42.
PRAX has been the subject of a number of research analyst reports. Royal Bank Of Canada reiterated an “outperform” rating and issued a $462.00 target price (up from $449.00) on shares of Praxis Precision Medicines in a research note on Friday, August 7th. BTIG Research boosted their target price on Praxis Precision Medicines from $810.00 to $826.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. The Goldman Sachs Group restated a “buy” rating and set a $575.00 price target (up from $470.00) on shares of Praxis Precision Medicines in a research report on Friday, August 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Praxis Precision Medicines in a research report on Monday, August 24th. Finally, UBS Group started coverage on Praxis Precision Medicines in a report on Wednesday, October 14th. They set a “buy” rating and a $706.00 price target for the company.
Check Out Our Latest Stock Report on Praxis Precision Medicines
Institutional Trading of Praxis Precision Medicines
Several large investors have recently made changes to their positions in the business. GAMMA Investing LLC increased its position in Praxis Precision Medicines by 10.3% in the 2nd quarter. GAMMA Investing LLC now owns 332 shares of the company’s stock valued at $111,000 after acquiring an additional 31 shares in the last quarter. KBC Group NV raised its stake in shares of Praxis Precision Medicines by 5.8% in the first quarter. KBC Group NV now owns 715 shares of the company’s stock worth $230,000 after acquiring an additional 39 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Praxis Precision Medicines by 0.9% in the third quarter. Nisa Investment Advisors LLC now owns 6,167 shares of the company’s stock worth $1,796,000 after acquiring an additional 56 shares during the last quarter. Carl P. Sherr & Co. LLC raised its stake in shares of Praxis Precision Medicines by 8.4% in the first quarter. Carl P. Sherr & Co. LLC now owns 972 shares of the company’s stock worth $313,000 after acquiring an additional 75 shares during the last quarter. Finally, Eagle Bay Advisors LLC raised its stake in shares of Praxis Precision Medicines by 11.3% in the third quarter. Eagle Bay Advisors LLC now owns 1,064 shares of the company’s stock worth $310,000 after acquiring an additional 108 shares during the last quarter. Institutional investors own 67.84% of the company’s stock.
Praxis Precision Medicines Stock Up 1.7%
Shares of PRAX stock opened at $264.49 on Friday. Praxis Precision Medicines has a 12-month low of $154.45 and a 12-month high of $392.70. The company has a market capitalization of $7.38 billion, a P/E ratio of -20.46 and a beta of 2.79. The firm has a 50-day moving average price of $317.43 and a 200 day moving average price of $317.78.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($2.87) EPS for the quarter, beating analysts’ consensus estimates of ($3.67) by $0.80. As a group, research analysts expect that Praxis Precision Medicines will post -14.15 earnings per share for the current year.
About Praxis Precision Medicines
Praxis Precision Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for disorders of the central nervous system. The company applies its Cerebrum™ platform, which combines human genetics, neuroscience and data science, to identify disease mechanisms and advance precision medicines for patients with neurological and psychiatric conditions.
Its pipeline has included investigational treatments for epilepsy and other severe neurological disorders. Key programs have included PRAX-628, a small-molecule antiseizure medicine candidate, and elsunersen, an antisense oligonucleotide program being developed for certain genetically defined forms of epilepsy.
Featured Stories
- Five stocks we like better than Praxis Precision Medicines
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
